Importantly, as observed in the clinic, these data also demonstrate a prevalent heterogeneity of response to a given perturbation even within subsets of models sharing a common oncogenic driver (heterogeneity of response within KRAS driven NSCLC models for example ref. 21). This evidence concerns the gene KRAS and non-small cell lung carcinoma.